Zamani M,Ebrahimtabar F,Zamani V,Miller W,AlizadehNavaei R,Shokri‐Shirvani J .2018 .Systematic review with meta‐analysis: the worldwide prevalence of Helicobacter pylori infection. Aliment Pharmacol Ther, 47(7) : 868-76.
Gunaratne AW,Hamblin H,Clancy A,Magat AJMC,Dawson MVM,Tu J .2021 .Combinations of antibiotics and vonoprazan for the treatment of Helicobacter pylori infectionsExploratory study. Helicobacter, 26(5) : e12830.
Argueta EA,Moss SF .2022 .How we approach difficult to eradicate Helicobacter pylori. Gastroenterology, 162(1) : 32-7.
Pourfarzi F,Moghadam TZ,Zandian H,Malekzadeh R,Yazdanbod A .2021 .Cost-effectiveness analysis of two routine therapeutic methods for Helicobacter pylori eradication: a Persian cohort-based study. Gastroenterol Hepatol Bed Bench, 14(3) : 250-9.
Aishwarya M,Kannan I,Sucharitha ST .2022 .In silico design of primers and development of PCR-RFLP test for the detection of antibiotic sensitivity in Helicobacter pylori. Glob J Innov Med Sci, 1(1) : 38-44.
Kamani L,Ahsan M,Butt N,Luxmi S,Khan JUA,Khan E .2022 .Helicobacter Pylori Management Guidelines from Pakistan. J Pak Med Assoc, 72(7 Suppl 2) : 4-11.
Chey WD,Mégraud F,Laine L,López LJ,Hunt BJ,Howden CW .2022 .Vonoprazan triple and dual therapy for Helicobacter pylori infection in the United States and Europe: Randomized clinical trial. Gastroenterology, 163(3) : 608-19.
Farhoud NS,Ibrahim OM,Ezzat SE .2020 .Efficacy and costeffectiveness comparison of 10-day, 14-day sequential versus 14-day triple therapies for treating Helicobacter pylori infection in Egyptian patients. J Clin Gastroenterol, 54(9) : 806-12.
Suzuki S,Gotoda T,Kusano C,Ikehara H,Ichijima R,Ohyauchi M .2020 .Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line Helicobacter pylori treatment: a multicentre randomised trial in Japan. Gut, 69(6) : 1019-26.
Maruyama M,Tanaka N,Kubota D,Miyajima M,Kimura T,Tokutake K .2017 .Vonoprazan-based regimen is more useful Submitted: May 28, 2023 than PPI-based one as a first-line Helicobacter pylori eradication: a randomized controlled trial. Can J Gastroenterol Hepatol, : 4385161.
Sun Y,Yue L,Hu W. Effectiveness .2023 .and safety of vonoprazanbased regimens compared with those of proton pump inhibitor (PPI)-based regimens as first-line agents for Helicobacter pylori: a meta-analysis of randomized clinical trials. Eur J Clin Pharmacol, 79(2) : 279-88.
Kajihara Y,Shimoyama T,Mizuki I. .2017 .Analysis of the costeffectiveness of using vonoprazan-amoxicillinclarithromycin triple therapy for first-line Helicobacter pylori eradication. Scand J Gastroenterol, 52(2) : 238-41.
Shehryar M,Ahmad RU,Kareem HK,Khan L,Ashraf MF,Hassan A .2022 .Efficacy, safety and cost-effectiveness of vonoprazan vs Proton Pump Inhibitors in reflux disorders and H. pylori eradication: A literature review. Ann Med Surg, 82 : 104760.